136834-18-9

Basic information

• Product Name: N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine
• Synonyms: N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine
• CAS NO: 136834-18-9
• Molecular Weight: 539.588
• Mol File: 136834-18-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine(CAS DataBase Reference)
• NIST Chemistry Reference: N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine(136834-18-9)
• EPA Substance Registry System: N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine(136834-18-9)

Safety Data

• Hazardous Substances Data: 136834-18-9(Hazardous Substances Data)

Upstream product

• 79896-97-2 N6-benzoyl-9-β-D-arabinofuranosyladenine 
• 110-87-2 3,4-dihydro-2H-pyran 
• 98-88-4 benzoyl chloride 
• 5536-17-4 arabinosyl adenine 

Downstream Products

• 136834-19-0 N⁶-benzoyl-9-<2-O-(trifluoromethylsulfonyl)-3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl>adenine 
• 1172119-72-0 C₂₇H₃₄FN₇O₅ 
• 5536-17-4 arabinosyl adenine 
• 136834-22-5 N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-3-fluoro-tetrahydrofuran-2-yl]purin-6-yl]benzamide 
• 136834-21-4 N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)3-fluoro-4-hydroxytetrahydrofuran-2-yl)9H-purin-6yl)benzamide triethylammonium salt 
• 146954-64-5 N⁶-benzoyl-2'-deoxy-2'-fluoro-3',5'-di-O-tetrahydropyran-2-yladenosine 
• 136834-20-3 N-(9-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 20187-82-0 2'-fluorodeoxyadenosine 

Relevant articles and documents

INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE

Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1).

Modulation of CEACAM1 expression

Compounds, compositions and methods are provided for modulating the expression of CEACAM1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding CEACAM1. Methods of using these compounds for modulation of CEACAM1 expression and for diagnosis and treatment of disease associated with expression of CEACAM1 are provided.

ANTISENSE MODULATION OF EDG1 EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of EDG1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG1. Methods of using these compounds for modulation of EDG1 expression and for treatment of diseases associated with expression of EDG1 are provided.